Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART22-65s cells |
Synonyms | |
Therapy Description |
CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially leads to lysis of tumor cells expressing CD22 and antitumor activity (NCI Drug Dictionary; Blood (2022) 140 (Supplement 1): 2376-2377). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART22-65s cells | anti-CD22 CAR T cells CART22-65s|anti-CD22 CAR 4-1BB-TCRz CART22-65s | CD22 Immune Cell Therapy 15 | CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially leads to lysis of tumor cells expressing CD22 and antitumor activity (NCI Drug Dictionary; Blood (2022) 140 (Supplement 1): 2376-2377). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03620058 | Phase I | CART22-65s cells + huCART19 CART22-65s cells | CART22 Alone or in Combination With huCART19 for ALL | Active, not recruiting | USA | 0 |